Malignant Melanoma

Title Average Ratingsort ascending
63 year old woman with stage III malignant melanoma 100.00%
Improvement of the recurrence-free interval using biological adjuvant therapy in uveal melanoma. 100.00%
Bio-Immune therapy according to Professor Thomas Tallberg, a cure for Melanoma? 96.67%
Metronomic schedule of temozolomide with conventional dose of cisplatin in metastatic melanoma. Sub-category: Melanoma Categor 90.00%
Artesunate in the treatment of metastatic uveal melanoma--first experiences. 90.00%
Artemisinin derivates in the treatment of Cancer 90.00%
A phase II study of chemoneuroimmunotherapy with platinum, subcutaneous low-dose interleukin-2 and the pineal neurohormone mela 90.00%
Does chemosensitivity-assay-directed therapy have an influence on the prognosis of patients with malignant melanoma stage IV? .. 90.00%
Disulfiram inhibits activating transcription factor/cyclic AMP-responsive element binding protein and human melanoma growth in a 90.00%
Combining agents that target the tumor microenvironment improves the efficacy of anticancer therapy. 90.00%
Systems biology: a therapeutic target for tumor therapy. 86.67%
Adjuvant vaccination with melanoma antigen pulsed dendritic cells (DCs) in stage III melanoma patients. 85.00%
Cannibalism of live lymphocytes by human metastatic but not primary melanoma cells 80.00%
Therapeutic vaccination with an autologous TriMix-Dendritic cell vaccine combined with sequential interferon alfa-2b in ........ 80.00%
Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy. 80.00%
Effect of indomethacin plus ranitidine in advanced melanoma patients on high-dose interleukin-2. 80.00%
Ukrain monotherapy in malignant melanoma (case report) 80.00%
Dendritic cell vaccination in melanoma patients: Update and subgroup analysis of clinical response to post-vaccine treatment. 80.00%
Disulfiram induces copper-dependent stimulation of reactive oxygen species and activation of the extrinsic apoptotic pathway in 80.00%
Optimizing a novel regional chemotherapeutic agent against melanoma: hyperthermia-induced enhancement of temozolomide cytot..... 80.00%
Effective treatment of advanced human melanoma metastasis in immunodeficient mice using combination metronomic chemotherapy regi 80.00%
Dendritic Cell Therapy 70.00%
Oral metronomic cyclophosphamide in elderly with metastatic melanoma. 70.00%
Effects of artemisinin and its derivatives on growth inhibition and apoptosis of oral cancer cells. 70.00%
Multicenter phase II study of temozolomide therapy for brain metastasis in patients with malignant melanoma, breast cancer...... 60.00%
Primary melanocytic tumor of the cerebellopontine angle mimicking a vestibular schwannoma: case report. 60.00%
Ukrain with chemotherapy in malignant melanoma (case report) 50.00%
Inhibition of angiogenesis by non-toxic doses of temozolomide. 50.00%
A metronomic schedule of cyclophosphamide combined with PEGylated liposomal doxorubicin.... 50.00%
Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomide. 50.00%
Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Onco 40.00%
Correlation between prior therapeutic dendritic cell vaccination and the outcome of patients with metastatic melanoma treated... 30.00%
The value of proteasome inhibition in cancer. Can the old drug, disulfiram, have a bright new future as a novel proteasome inhib 0.00%